The cost of stroke in a public hospital in Brazil: a one-year prospective study

Custo do AVC em um hospital público no Brasil: um estudo prospectivo de um ano

Juliana SAFANELLI1, Luana Gabriela Dalla Rosa VIEIRA2, Tainá de ARAUJO3, Lidiana Fachinete Silva MANCHOPE2, Maria Helena Ribeiro KUHLHOFF1, Vivian NAGEL1, Adriana Bastos CONFORTO2,3,4, Gisele Sampaio SILVA5, Suleimy MAZIN6, Pedro Silva Corrêa de MAGALHÃES7, Norberto Luiz CABRAL1

ABSTRACT

Low- and middle-income countries face tight health care budgets, not only new resources, but also costly therapeutic resources for treatment of ischemic stroke (IS). However, few prospective data about stroke costs including cerebral reperfusion from low- and middle-income countries are available. Objective: To measure the costs of stroke care in a public hospital in Joinville, Brazil. Methods: We prospectively assessed all medical and nonmedical costs of inpatients admitted with a diagnosis of any stroke or transient ischemic attack over one year, analyzed costs per type of stroke and treatment, length of stay (LOS) and compared hospital costs with government reimbursement. Results: We evaluated 274 patients. The total cost for the year was US$1,307,114; the government reimbursed the hospital US$1,095,118. We found a significant linear correlation between LOS and costs (r = 0.71). The median cost of 134 IS inpatients who did not undergo cerebral reperfusion (National Institutes of Health Stroke Scale [NIHSS] median = 3) was US$2,803; for IS patients who underwent intravenous (IV) alteplase (NIHSS 10), the median was US$5,099, and for IS patients who underwent IV plus an intra-arterial (IA) thrombectomy (NIHSS > 10), the median was US$10,997. The median costs of a primary intracerebral hemorrhage, subarachnoid hemorrhage, and transient ischemic attack were US$2,436, US$8,031 and US$2,677, respectively. Conclusions: Reperfusion treatments were two-to-four times more expensive than conservative treatment. A cost-effectiveness study of the IS treatment option is necessary.

Keywords: Stroke; hospital custs; cost of illness; socioeconomic factors.

RESUMO

Os países de baixa e media renda enfrentam orçamentos apertados na saúde, não somente devido aos novos recursos terapêuticos, mas também relacionado ao custo oneroso do tratamento do acidente vascular cerebral. No entanto, poucos dados prospectivos sobre os custos do AVC, incluindo reperfusão cerebral de países de baixa e média renda estão disponíveis. Objetivo: Mensurar os custos do atendimento ao AVC em um hospital público. Métodos: Avaliamos prospectivamente todos os custos médicos e não médicos de pacientes internados com diagnóstico de acidente vascular cerebral e/ou AIT durante um ano, analisamos o custo por tipo de AVC e tratamento, tempo de permanência e compomos os custos hospitalares com o reembolso governamental. Resultados: Foram avaliados 274 pacientes. O custo total em um ano foi de US$ 1,307,114; o governo reembolsou o hospital no valor de US$ 1,095,118. Encontramos uma correlação linear significativa entre LOS e custos (r = 0.71). A mediana do custo do AVC em 134 pacientes que não sofreram reperfusão cerebral (National Institutes of Health Stroke Scale [NIHSS] median = 3) foi de US$ 2,803; para pacientes submetidos a alteplase intravenosa (IV) (NIHSS 10), a mediana foi de US$ 5,099 e para pacientes submetidos a trombectomia intra-arterial (IA) (NIHSS > 10), o custo mediano foi de US$ 10,997. A mediana do custo de uma hemorragia intracerebral primária, hemorragia subaracnóidea e AIT foram de US$ 2,436, US$ 8,031 e US$ 2,677, respectivamente. Conclusões: Os tratamentos de reperfusão foram duas a quatro vezes mais caros do que o tratamento conservador. Estudo de custo-efetividade para o tratamento do AVC são necessários.

Palavras-chave: Acidente vascular cerebral; custos hospitalares; efeitos psicossociais da doença; fatores socioeconômicos.

1Universidade da Região de Joinville, Joinville Stroke Registry, Programa de Pós-Graduação em Saúde e Meio Ambiente, Joinville, SC, Brasil; 2Universidade da Região de Joinville, Joinville Stroke Registry, Programa de Pós-Graduação em Saúde e Meio Ambiente, Joinville, SC, Brasil; 3Universidade Federal de São Paulo, Divisão de Clínica Neurológica, São Paulo, SP, Brasil; 4Hospital Israelita Albert Einstein, São Paulo, SP, Brasil; 5Universidade de São Paulo, Hospital das Clínicas, São Paulo, SP, Brasil; 6Universidade de São Paulo de Ribeirão Preto, Hospital das Clínicas, Ribeirão Preto, SP, Brasil; 7Hospital Municipal São José, Unidade de AVC, Joinville, SC, Brasil.

Juliana Safanelli; Universidade da Região de Joinville; Rua Paulo Malschitzki, 10; 89219-710 Joinville SC, Brasil; E-mail: juliana.safanelli@gmail.com

Conflict of interest: There is no conflict of interest to declare.

Support: This study was supported by the National Council for Scientific and Technological Development, CNPq Grant 402396/2013-8.

Received 21 September 2018; Received in final form 07 January 2019; Accepted 18 February 2019.
Epidemiological data predict a worldwide increase in the cost of strokes\textsuperscript{12}. One of the main reasons is the increase in the prevalence that will result from falling mortality rates\textsuperscript{1}. Data are scarce about stroke costs in low- and middle-income countries, but in high-income countries, an average of 3% of the government health care budget is spent on stroke costs\textsuperscript{3}. This amount includes hospital costs and indirect costs due to productivity losses and premature mortality\textsuperscript{4}. Hospital costs have been estimated to represent anywhere between 28% and 83% of the total cost of strokes, the percentage being largely determined by the calculation method used for social costs\textsuperscript{4,5}.

In Brazil, the state-run health care system is universal. Three quarters of the population use it exclusively and one quarter uses both public and private health services\textsuperscript{6}. In 2013, 12.1 million people were hospitalized in Brazil, and eight million benefited from the public health system\textsuperscript{7}. Stroke units and cerebral reperfusion options have become national public health priorities\textsuperscript{8}, but the Brazilian Ministry of Health does not have an up-to-date information system, so cost data are missing. In São Paulo, a retrospective study published in 2009 estimated in-hospital costs to be US$4,101 for primary intracerebral hemorrhage (PIH) and US$1,902 for ischemic stroke (IS)\textsuperscript{8}. We aimed to measure public in-hospital costs for IS with and without cerebral reperfusion, PIH, subarachnoid hemorrhage (SAH), and transient ischemic attack (TIA) in Joinville, Brazil.

**METHODS**

**Study population**

The Joinville Stroke Registry is an ongoing population-based study that has been running since 2005. Its methods have been extensively published elsewhere\textsuperscript{10}. The cost of illness was extracted from the Hospital Municipal São José, a reference public hospital that serves 1.2 million people in the northeastern region of the state of Santa Catarina. In 2017, Joinville had a score of 0.809 in the human development index (ranking 21\textsuperscript{e} among 5,570 Brazilian cities).

**Official payment data**

To define the amount of government payments, the Unified Health System (SUS) uses a unified table of procedures called System of Management of the Table of Procedures and Medications\textsuperscript{11}. The SUS refunds US$611 for IS that requires a hospital stay of up to seven days. If the patient undergoes intravenous thrombolysis, the refund is US$1,219, and unfortunately the intra arterial thrombectomy is not yet reimbursed by the Brazilian Health System\textsuperscript{11,12}. We used the criteria for health costs management from the Ministry of Health for our hospital cost definitions\textsuperscript{12}.

**Pilot study**

In the absence of standard methodology in computing the direct costs of stroke in a public hospital in Brazil, we conducted a pilot study in August 2016. For each patient, the principal investigator verified all checklist items daily during the hospital stay. Other data such as demographic, socioeconomic information, stroke scales (clinical and functional), and clinical outcomes were extracted from the Joinville Stroke Registry\textsuperscript{10,13}. In this study phase, we compared all final bills for each patient with account department data.

**Method and period of data collection**

This was a cost-of-illness and one-year prevalence-based study\textsuperscript{14}. We prospectively extracted the data from September 1, 2016 to August 30, 2017. We included subjects with IS, PIH, SAH and TIA, first-ever or not, aged ≥ 18 years. We excluded patients with incomplete medical records and those who were transferred from another hospital. The IS severity was stratified according to the National Institutes of Health Stroke Scale (NIHSS): 1–3 (minor); 4–10 (moderate) and > 10 (severe)\textsuperscript{15}.

**Daily hospital cost**

The daily hospital cost was a composition of medical and nonmedical costs. Direct medical costs included all items that encompass patient care—such as medical, nursing, and rehabilitation attendance and procedures; diagnosis work-ups; all items with medical and nursing prescriptions; diets for patients and companions; and items for personal hygiene. Table 1 shows the daily hospital composition among health care professionals to obtain the final cost per patient per day. The costs of diagnosis work-up included the unit price of each biochemical and radiological tests. The unit cost of each biochemical examination was the sum of the fraction of all personal labour costs and material costs for blood extraction and analysis. As cranial tomography and magnetic resonance imaging services are outsourced, the values were extracted from the System of Management of the Table of Procedures, Medications and Office of Personal Management of SUS (SIGTAP)\textsuperscript{11}.

The unit costs of electrocardiograms, X-rays, video fluoroscopic swallowing studies, and carotid ultrasound and transcranial Doppler investigations included the material costs of each examination plus the labour-hour costs of all professionals of the radiology sector. Daily medical prescription items included all drugs, intravenous fluids and medicinal gases, whose costs were obtained in the purchasing sector according to the Brasindice 2016 table\textsuperscript{16}. The nonmedical components of the daily hospital cost were electrical power consumption (kw), water (m\textsuperscript{3}), garbage and laundry collection, and kitchen, pharmacy, sanitation, and cleaning personnel.

**Administrative fees**

We included the costs of administrative assistants. All wages, labour and employer expenses, and costs for benefits...
such as food and transportation vouchers were added together, and the total was divided by the annual average of attendance. The consumption per patient per day were calculated based on absorption and apportionment costing methods.\[17\]

**Statistical analysis**

We evaluated the differences among patient subgroups by using a χ² test, t test, or Mann-Whitney U test as appropriate. All tests were two tailed. We converted the cost data to the 2013 currency values by using a web-based tool (CCEMG-EPPI-Centre cost converter). First, it converted the cost into Brazil’s current cost per year by using the gross domestic product (GDP) deflator index, and then it converted this cost into US dollars (US$) (for the year 2016) by using conversion rates based on purchasing power parity (PPP) for the GDP (Brazil’s real PPP value in 2016 was 0.49). For comparison, we also converted the original costs of other studies to costs for the year 2016. We ran the tests in Statistical Analysis System software, version 9.2, with PROC GENMOD (SAS Institute, Inc., Cary, NC). The study was approved by the ethics in research committees of the hospital and university involved.

**RESULTS**

We calculated the costs of 274 patients. From those, 71% (196/274) had IS, 12% (34/274) had TIA, 11% (31/274) had PIHs, and 6% (13/274) had SAHs. The mean age was 60 years old (SD=±27). The median NIHSS was 6 for IS patients (IQR: 6–12), 7 (IQR: 4–17) for PIH patients, and 8 (IQR: 8–18) for SAH patients. Among the 196 IS patients, 32% (63) had mild strokes (NIHSS: 1–3), 37% (73) had moderate strokes (NIHSS: 4–10), and 31% (60) had severe strokes (NIHSS: > 10). The case-fatality at 30 days was 14% (28/196) for IS patients, 25% (8/31) for PIH patients and 53% (7/13) for SAH patients. The length of stay (LOS) was 13 days (SD ± 12) for IS patients, 12 days (SD ± 13) for PIH patients, 14 days (SD ± 6) for SAH patients, and 11 days (SD ± 5) for TIA patients.

The overall cost for all 247 stroke patients who were admitted during one year was US$1,307,114 and the SUS reimbursed US$1,095,118. Table 2 shows the total costs and daily costs by stroke type.

As expected, the cost of IA thrombectomy was three to four times higher than that of intravenous (IV) reperfusion (p < 0.001). There was no statistical difference in age between...
IS patients treated with or without cerebral reperfusion (p = 0.72; Table 4).

The proportions of costs, including daily hospital costs, drug costs, costs for medical procedures, costs for diagnosis work-ups, costs for medical gases, and diet and administration fees are available in Figure 4. Table 5 shows the unit costs of each item and the average cost per stroke type over the year. Daily hospital costs in the emergency, intensive care, and stroke unit sectors made up 53% of all the final bills (US$695,991 of US$1,307,114). The second most expensive item was the category of medical procedures. The proportion of costs for diagnostic work-up ranged from 15% for TIA to 4% to SAH patients. These procedures made up 16% of the total bill (US$211,366 of US$1,307,114). The intra-arterial thrombectomy, which were performed in 7% of all patients (21/274), made up 12% (US$158,331 of US$1,307,114) of the total bill.

DISCUSSION

In a public hospital using a prospective micro-costing methodology, the overall in-hospital cost of 274 strokes over one year was approximately US$1.3 million; the government reimbursed approximately $1.1 million. The median stroke cost per patient was US$7,470. Therefore, the Brazilian Health System stroke underfunding is a tremendous hurdle to overcome. Thrombolysis and thrombectomy have been performed at the hospital since 2005. We found that the in-hospital cost of an IS with cerebral reperfusion was significantly more expensive than conservative treatment, reaching, for those who underwent combined reperfusion, four times higher costs.

The overall per-day costs were approximately US$400 and, regardless of stroke type, all costs increased with LOS and clinical severity. Our mean LOS was around two weeks for major strokes and around 11 days for a TIA. We compared these data with those of other studies from developing countries and found that our IS LOS (13 days) was shorter than that of patients in China (average of 20 days); similar to that of patients in India, Brazil, and Turkey; and higher than that of patients in Thailand (eight days) and Malaysia (six days) and, Pakistan (five days).

Many pitfalls exist in analyses of stroke costs in countries at different times. In order to compare our findings with those regarding the costs of other hospitals, we adjusted the costs of the original studies to the GDP deflator index and PPP in 2016. Therefore, our median IS cost of US$2,803 (without cerebral reperfusion) was higher than the costs in Thailand (US$1,800 and Turkey (US$1,406) but lower than the cost in Argentina (US$3,778). In our IS sample, 31% of patients underwent cerebral reperfusion. Our median cost for IS IV lysis was US$5,099, and the median cost for IV+IA lysis was US$10,997. These amounts were much lower than the amount in the United States. For instance, the median hospital cost for IS patients who received IV thrombolysis from 2001 to 2008 was US$63,472 in the United States and US$14,102 in Brazil (IQR: 9,987–20,819). Studies in the United States have reported costs even higher than this median cost. For IV lysis, costs in the United States ranged

Table 3. Hospital costs by stroke type and LOS.

<table>
<thead>
<tr>
<th>Title</th>
<th>IS (n = 196)</th>
<th>PIH (n = 31)</th>
<th>SAH (n = 13)</th>
<th>TIA (p = 34)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 week US$</td>
<td>1,194 (1,088–1,705)</td>
<td>2,283 (1,239–4,023)</td>
<td>–</td>
<td>2,532 (1,727–3,563)</td>
<td>0.041</td>
</tr>
<tr>
<td>2 weeks US$</td>
<td>2,773 (2,291–3,720)</td>
<td>2,424 (1,334–4,545)</td>
<td>7,871 (6,469–9,449)</td>
<td>2,419 (2,182–3,429)</td>
<td>0.018</td>
</tr>
<tr>
<td>&gt; 2 weeks US$</td>
<td>5,231 (4,214–7,893)</td>
<td>2,507 (2,066–4,869)</td>
<td>9,956 (8,120–10,885)</td>
<td>2,823 (2,258–3,816)</td>
<td>0.003</td>
</tr>
<tr>
<td>LOS (days)</td>
<td>13 (12)</td>
<td>12 (13)</td>
<td>14 (6)</td>
<td>11 (5)</td>
<td>0.75</td>
</tr>
</tbody>
</table>

LOS: length of stay values in means (SD); cost values are adjusted median cost (IQR); United States dollars (US$).
from US$24,817 to US$33,810, and for IV+IA lysis, the costs in the United States ranged from US$39,825 to US$40,743.

Our cost for PIH patients who underwent surgery (US$17,709) was higher than the cost reported in 2009 in São Paulo (US$11,455). However, in both studies, the samples were very small (2/31 in Joinville and 6/45 in São Paulo). A recent cohort study conducted in Canada on the median cost for 987 patients with PIH, reported that the median cost ranged from US$4,685 (2,761–7,196) to US$8,867 (3,867–13,612).

Subarachnoid hemorrhages were the most expensive among all the stroke types; we found that the median cost for them was US$8,031. Few studies focused on inpatient costs of aneurysmal SAHs. Our SAH in-hospital costs were lower than those in Germany (US$13,980), the United States (US$41,905), Singapore (US$13,673), and Australia (US$25,880). All of these were lower than in the United States, where the median costs of hospitalization were US$79,916 for clipped patients and US$56,910 for coiled patients.

Our TIA median cost was US$2677. This amount is lower than the median cost of US$3,173 in the Netherlands. In a retrospective study with 21,653 TIA patients, the mean LOS was five days, which is much lower than our LOS of 11 days. In this Dutch study, the cost difference between inpatient Is (US$6,845) and inpatient TlAs (US$3,173) was caused by a shorter LOS for TIA patients (3.6 days vs 8.8 days for IS patients), which could have been expected, given the lower severity and shorter symptom duration of TlAs. The waiting...
TIA: transient ischemic attack; SAH: subarachnoid hemorrhage; PIH: primary intracerebral hemorrhage.

**Figure 4.** Composition of hospital costs by type of stroke.

**Table 5.** Unit costs and average composition of costs by stroke type.

<table>
<thead>
<tr>
<th>Cost item</th>
<th>Unit costs</th>
<th>IS (n = 196)</th>
<th>PIH (n = 31)</th>
<th>SAH (n = 13)</th>
<th>TIA (n = 34)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital stay</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emergency department</td>
<td>184.91</td>
<td>116,879.21</td>
<td>45,857.68</td>
<td>2,043.83</td>
<td>34,075.48</td>
</tr>
<tr>
<td>Intensive care days</td>
<td>304.62</td>
<td>–</td>
<td>–</td>
<td>29,800.30</td>
<td>–</td>
</tr>
<tr>
<td>Stroke unit</td>
<td>153.51</td>
<td>371,056.52</td>
<td>21,532.32</td>
<td>33,281.03</td>
<td>23,369.42</td>
</tr>
<tr>
<td>Visits</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical</td>
<td>15.32</td>
<td>46,032.64</td>
<td>5,699.04</td>
<td>7,589.08</td>
<td>3,646.16</td>
</tr>
<tr>
<td>On-call</td>
<td>28.19</td>
<td>29,575.72</td>
<td>3,495.56</td>
<td>4,366.47</td>
<td>9,560.80</td>
</tr>
<tr>
<td>Medical procedures</td>
<td>728.46*</td>
<td>11,655.36</td>
<td>5,832.42</td>
<td>30,587.34</td>
<td>4,961.50†</td>
</tr>
<tr>
<td>Thrombectomy</td>
<td>6,884.12</td>
<td>158,311.64</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Physiotherapy</td>
<td>9.09</td>
<td>24,253.12</td>
<td>2,254.32</td>
<td>890.85</td>
<td>545.40</td>
</tr>
<tr>
<td>Occupational therapy</td>
<td>9.09</td>
<td>5863.28</td>
<td>163.62</td>
<td>218.17</td>
<td>309.06</td>
</tr>
<tr>
<td>Speech therapy</td>
<td>9.09</td>
<td>10,808.20</td>
<td>2,817.90</td>
<td>827.19</td>
<td>309.06</td>
</tr>
<tr>
<td>Psychotherapy</td>
<td>7.67</td>
<td>3,006.64</td>
<td>713.31</td>
<td>498.55</td>
<td>–</td>
</tr>
<tr>
<td>Diagnostic and imaging tests</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT (brain)</td>
<td>47.62</td>
<td>24,667.04</td>
<td>1,952.42</td>
<td>1,238.12</td>
<td>2,127.08</td>
</tr>
<tr>
<td>Carotid ultrasound</td>
<td>58.31</td>
<td>11,428.76</td>
<td>–</td>
<td>–</td>
<td>1,982.54</td>
</tr>
<tr>
<td>ECG</td>
<td>14.87</td>
<td>2,914.52</td>
<td>490.71</td>
<td>193.31</td>
<td>505.58</td>
</tr>
<tr>
<td>X-ray (thorax)</td>
<td>30.13</td>
<td>11,810.96</td>
<td>2,802.09</td>
<td>738.38</td>
<td>1,024.42</td>
</tr>
<tr>
<td>MRI (brain)</td>
<td>197.03</td>
<td>13,411.00</td>
<td>394.06</td>
<td>197.03</td>
<td>5,713.96</td>
</tr>
<tr>
<td>MRA, CTA</td>
<td>181.82</td>
<td>8,588.30</td>
<td>–</td>
<td>330.20</td>
<td>2,181.84</td>
</tr>
<tr>
<td>Echocardiogram TT</td>
<td>25.65</td>
<td>6,283.20</td>
<td>153.90</td>
<td>–</td>
<td>1,297.10</td>
</tr>
<tr>
<td>Laboratory investigations†</td>
<td>75.56</td>
<td>16,809.76</td>
<td>3,342.36</td>
<td>3,691.75</td>
<td>2,774.80</td>
</tr>
<tr>
<td>Drugs</td>
<td>6.08</td>
<td>14,297.16</td>
<td>974.11</td>
<td>16,522.54</td>
<td>238.41†</td>
</tr>
<tr>
<td>r-tPA- alteplase</td>
<td>408.11</td>
<td>35,097.90</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Antibiotics</td>
<td>12.22</td>
<td>10,597.43</td>
<td>2,737.28</td>
<td>1,510.80</td>
<td>–</td>
</tr>
<tr>
<td>Medicinal gases</td>
<td>21.82</td>
<td>5,923.26</td>
<td>2,285.23</td>
<td>1,710.65</td>
<td>–</td>
</tr>
<tr>
<td>Administrative fees</td>
<td>60.35</td>
<td>11,828.60</td>
<td>1,870.85</td>
<td>784.56</td>
<td>2,051.90</td>
</tr>
<tr>
<td>Sub-totals</td>
<td>976,069.42</td>
<td>108,382.59</td>
<td>124,979.31</td>
<td>97,685.01</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1,307,114.10</td>
</tr>
</tbody>
</table>

*Medical procedures included all neurosurgical and neuroradiological procedures plus general surgery operations. The unit costs are in means. † Mean of all biochemistry, cytopathological, and bacteriological examinations. Values in United States dollars (US$). MRI: magnetic resonance image; MRA: magnetic resonance angiography; CTA: computed tomography angiography; TT: transthoracic.
time for diagnosis work-ups was the main reason for the high LOS of our TIA patients.

Our study has some limitations. The first and most important limitation is the absence of a structured cost centre at the Hospital Municipal São José. Therefore, extracting from the pilot phase were matched with the financial-hospital sector, our comprehensive methods have not yet been validated. Still, no gold standard method exists for the evaluation of the costs of strokes. Second, our samples of patients with IS who underwent IA lysis, patients with PH, and patients who underwent surgery were very small. Third, this was a single-centre study and, therefore, the potential for extrapolation of data to the national level is limited. The study’s strengths include a prospective design covering all daily medical and nonmedical items over one year in a public setting.

In conclusion, stroke is a costly disease. For SAH and IS patients, mechanical thrombectomy and greater lengths of stay were associated with greater costs, as described in studies performed in other countries. Further studies evaluating the cost-effectiveness for IS cerebral reperfusion in developing countries are sorely needed. The Brazilian Health System is underfunding the stroke costs in our setting.

References


